Medical

GLP-1 agonists (semaglutide, tirzepatide)

15–20% weight loss in obesity and 20% fewer cardiovascular events — the first “metabolic drug” to move hard endpoints in non-diabetics.

Impact 4/55/5· Replicated RCTs, guidelinesEffort: a habit

First step today

With BMI ≥30, talk to an endocrinologist or obesity specialist.

How

Medical indication: BMI ≥30, or ≥27 with comorbidity. Weekly injection, gradual titration; protein and strength training are MANDATORY alongside, or 25–40% of the loss is muscle.

Evidence

SELECT (n=17,604, 3.3 years, non-diabetic overweight): semaglutide –20% major cardiovascular events. SURMOUNT-1: tirzepatide –20.9% body weight over 72 weeks. Side effects: nausea, gallstones, rarely pancreatitis.

Goals

Body weightHeart, blood sugar

Related studies

SELECT: semaglutide cuts cardiovascular events 20% in non-diabetics · 2023
SELECT: semaglutide cuts cardiovascular events 20% in overweight non-diabetics · 2023

Sources

Lincoff AM et al. SELECT – Semaglutide and cardiovascular outcomes in obesity without diabetes. NEJM (2023) ↗
Jastreboff AM et al. SURMOUNT-1 – Tirzepatide once weekly for the treatment of obesity. NEJM (2022) ↗

Last reviewed: 6 September 2026

This site is educational and does not replace medical advice. Start any supplement or drug only after consulting a doctor or pharmacist.